Clinical Trial Update: A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SCD411 to Eylea in wet/ neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• SCD411 (SCD411)

Snippet

Sponsor: Sam Chun Dang Pharm. Co. Ltd. | Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2023-10-10